XL999 has the potential to provide benefit to patients with lung cancer and acute myelogenous leukemia. XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases... XL999 has the potential to prevent tumor growth — both directly by a novel effect on tumor cell proliferation and indirectly through inhibition of the host angiogenic response.
- Mechanism
- Curator reviewed
XL999 is a potent inhibitor of key receptor tyrosine kinases implicated in the development and maintenance of tumor vasculature and in the proliferation of some tumor cells. It inhibits FGFR1, FGFR3, RET, VEGFR2 and PDGFR, and is also a potent inhibitor of FLT3, an important driver of leukemia cell proliferation in some patients with acute myelogenous leukemia (AML). XL999 exhibited excellent activity in target-specific cellular functional assays.
- Primary indication
- Investigated for use/treatment in cancer/tumors (unspecified), lung cancer, and solid tumors.Curator reviewed
- Code names
- XL999
Resolves to
What you can answer from here — as of October 01, 2026
Which drugs share a target with XL999, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account